Xenon Pharmaceuticals Inc. XENE
NASDAQ · United States · Health Technology
$39.77+2.58 (+6.94%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
CEO Ian Mortimer and CFO Thomas Kelly purchased 45,000 shares of XENE in the open market.
Xenon Pharmaceuticals' (XENE) safety data has raised investor concerns about a potential Food and Dr
Toronto, Ontario--(Newsfile Corp. - September 29, 2026) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce Ian Mortimer, President and Chief Executive Officer of Xenon Pharmaceuticals, as the recipient of the 2026 Bloom Burton Award. 2026 Bloom Burton Award Winner Ian Mortimer, President and Chief Executive Officer of Xenon PharmaceuticalsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/6420/316465_7cc4242184cef922_001full.jpgIn the past..
Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee.Sherry Aulin is a finance executive with more than
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) advanced its epilepsy program while encountering a new obstacle to expansion. On September 17, it submitted a New Drug Application to the U.S. Food and Drug Administration for azetukalner in focal seizures, which originate in a specific area of the brain. The same announcement disclosed a voluntary pause in new enrollment […]
Wall Street reacts as the drugmaker’s experimental medication hits a roadblock.
VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference: TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit, Virtual Fireside Chat: Wednesday, September 23, 2:00–2:25 pm ET Details a
Companies in The News Are: STLD,XENE,AMD,TXN
Key Stats for Xenon Pharmaceuticals StockPrice change for Xenon Pharmaceuticals stock: -31%$XENE Stock Price as of Sep. 19: $4052-Week High: $73$XENE Stock Price Target: $78What Happened?Xenon Pharmaceuticals (XENE) stock is under pressure after the company paused enrollment in its Phase 3 psychiatry studies for major depressive disorder and bipolar disorder.
Earlier this month, Xenon Pharmaceuticals submitted a New Drug Application to the US FDA for azetukalner in focal seizures, supported by two randomized, double-blind, placebo-controlled trials showing statistically significant seizure reduction and a generally consistent safety profile across more than 1,500 patient-years of exposure. On the same day, the company voluntarily paused new enrollment in its Phase 3 major depressive disorder and bipolar depression studies due to neuropsychiatric...
Xenon Pharmaceuticals voluntarily halted enrollment in a handful of studies Friday due to several unexpected side effects. The biotech stock crashed to a 10-month low.
Xenon Pharmaceuticals stock sinks as the company halts enrollment of new patients in a key trial. Here’s how you should play XENE shares at current levels.
Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.’
Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index decreasing 0.5% and th
Xenon Pharmaceuticals Inc. (XENE:NASDAQ) shares were down 30%, on Friday morning after the company voluntarily halted new enrollment in major depressive disorder and bipolar depression studies. The events were consistent with azetukalner's known safety profile, Xenon said, but had not...
Xenon Pharmaceuticals' (XENE) enrollment pause in an ongoing phase 3 trial of azetukalner adds risk
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) submitted a New Drug Application to the U.S. Food and Drug Administration for its investigational drug azetukalner to treat focal seizures. Simultaneously, the neuroscience-focused biopharmaceutical company announced a voluntary pause on new patient enrollment in its ongoing depression clinical studies following reports of neuropsychiatric adverse events. Positive Data Drives FDA Submission The regulatory filing relies on clinical data from the Phase 2b X
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.